KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $149.4 million.

  • Vertex Pharmaceuticals' Capital Expenditures rose 6133.91% to $149.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $437.6 million, marking a year-over-year increase of 4699.36%. This contributed to the annual value of $437.6 million for FY2025, which is 4699.36% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Capital Expenditures stood at $149.4 million for Q4 2025, which was up 6133.91% from $101.8 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Capital Expenditures registered a high of $149.4 million during Q4 2025, and its lowest value of $33.6 million during Q4 2022.
  • In the last 5 years, Vertex Pharmaceuticals' Capital Expenditures had a median value of $60.7 million in 2021 and averaged $68.8 million.
  • Within the past 5 years, the most significant YoY rise in Vertex Pharmaceuticals' Capital Expenditures was 26452.44% (2021), while the steepest drop was 7002.2% (2021).
  • Over the past 5 years, Vertex Pharmaceuticals' Capital Expenditures (Quarter) stood at $61.8 million in 2021, then tumbled by 45.63% to $33.6 million in 2022, then soared by 72.92% to $58.1 million in 2023, then skyrocketed by 59.38% to $92.6 million in 2024, then skyrocketed by 61.34% to $149.4 million in 2025.
  • Its Capital Expenditures stands at $149.4 million for Q4 2025, versus $101.8 million for Q3 2025 and $145.7 million for Q2 2025.